Frequent activation of phosphatidylinositol-3 kinases (PI3K)/Akt/mTOR signaling pathway in gastric cancer (GC) is gaining immense popularity with identification of mutations and/or amplifications of PIK3CA gene or loss of function of PTEN, a tumor suppressor protein, to name a few; both playing a crucial role in regulating this pathway. These aberrations result in dysregulation of this pathway eventually leading to gastric oncogenesis, hence, there is a need for targeted therapy for more effective anticancer treatment. Several inhibitors are currently in either preclinical or clinical stages for treatment of solid tumors like GC. With so many inhibitors under development, further studies
PI3K/AKT/MTOR PATHWAY
Several members of PI3K/Akt/mTOR pathway play a crucial role in regulating this pathway and hence, maintaining cellular homeostasis under normal physiological conditions. Some of these essential components are described below.
PI3K
PI3K are a family of lipid kinases known to phos phorylate the inositol ring of the 3OH group in inositol phospholipids. They are further classified into three classes: Class Ⅰ, Ⅱ, and Ⅲ based on primary structure and regulation [1] . However, till date only Class Ⅰ, assisting in tight regulation of this pathway, has been shown to be associated with cancer. Class Ⅰ PI3K is a heterodimeric enzyme, with a catalytic and a regulatory subunit. The catalytic subunits for class Ⅰ PI3Ks are p110α, p110β, p110γ, and p110δ. It is further subdivided into class1A, encompassing p110α, p110β, and p110δ with a p85α, p85β, and p55γ regulatory subunit, and class1B consisting of only p110γ with p101, p84, and p87PIKAP regulatory subunits. A typical regulatory subunit has several proteinprotein interacting domains, one of them, the interSH2 domain (iSH2) interacts with the p110 catalytic subunit, stabilizing p110 and its activities [2] . Reports have suggested the p110α subunit encoded by the PIK3CA gene as being the only catalytic subunit associated with several cancers [3] . p110α typically links with p85α, which is the most highly expressed regulatory subunit. The substrate for class1 PI3K, phosphatidylinositol 4,5biphosphate (PI4,5P2), generates the second messenger phosphatidylinositol3,4,5triphosphate (PI3,4,5P3).
Akt
Serine/threonine protein kinase Akt belongs to the AGC [named after the protein kinase A, G, and C families (PKA, PKC, PKG)] family of kinases. Three highly homologous isoforms (Akt1, Akt2, and Akt2) of Akt have been identified so far. Structurally, Akt is mainly comprised of three domains: an Nterminal pleckstrin homology (PH) domain, a central kinase catalytic domain (CAT), and a Cterminal extension (EXT) containing a regulatory hydrophobic motif (HM). Phosphorylation of residues in both the catalytic and Cterminal extension domain is essential for complete activation of Akt downstream of PI3K signaling. PDK1 selectively phosphorylates Thr (308) on the CAT domain of Akt, while the kinases responsible for phosphorylation of Ser (473) on the EXT domain of Akt are still unknown [4] . Thus, phosphorylation of both Ser (473) and Thr (308) residues on Akt is required for its complete activation [5, 6] . Fully activated Akt further regulates several processes downstream, along with positive regulation of mTOR and thereby mediating on predictive biomarkers are needed to measure the specificity of any therapeutic intervention. Herein, we review the common dysregulation of PI3K/Akt/mTOR pathway in GC and the various types of single or dual pathway inhibitors under development that might have a superior role in GC treatment. We also summarize the recent developments in identification of predictive biomarkers and propose use of predictive biomarkers to facilitate more personalized cancer therapy with effective PI3K/Akt/mTOR pathway inhibition.
Core tip: Gastric cancer (GC) is the fifth most common cancer in the world with highest incidence rate in Eastern Asia and Latin America. With increase in GC patient relapse and drug resistance, targeted therapy is gaining immense popularity for GC treatment. One of the pathways which has been reported to be dysregulated is phosphatidylinositol-3 kinases (PI3K)/Akt signaling pathway. This review focuses on how this pathway is crucial in GC oncogenesis. We also summarize the single or dual PI3K/Akt pathway inhibitors under investigation for GC treatment. Thereby, we discuss the plausible novel biomarkers under investigation for a more tailored approach for GC treatment.
INTRODUCTION
The phosphatidylinositol3 kinases/Akt (PI3K/Akt) signaling pathway is activated by several cellular stimuli regulating various physiological functions such as cell growth, cell survival, cell cycle progression, protein translation, and metabolism. Dysregulation of this pathway is frequently observed in several cancers including gastric cancer (GC). Hence, a deeper understanding of this signaling pathway would help target this pathway effectively using different therapeutic approaches. In this review we will focus on how this pathway is regulated in GC and the current status of using PI3K/Akt/mammalian target of rapamycin (mTOR) targeted therapy for GC treatment. mTOR activation.
mTOR
The mTOR protein, a 289kDa serine/threonine kinase, is a master regulator of cell growth. It can be distinguished into two distinct multiprotein complexes; mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). The mTORC1 complex is composed of mTOR, regulatoryassociated protein of mTOR (Raptor), mammalian lethal with SEC13 protein8 (MLST8), PRAS40, and DEPTOR. It functions downstream of Akt, integrating the Akt and mTOR pathway with 4EBP1 and S6K, which are immediate downstream targets of the mTORC1complex. The mTORC2 complex, on the other hand, is composed of rapamycininsensitive companion of mTOR, MLST8 and mammalian stressactivated protein kinase interacting protein 1. This complex functions upstream of Akt/PKB and plays a role in complete activation of Akt by phosphorylating Akt at the Ser473 residue. Hence, downstream substrates of the mTORC2 complex include Akt [7] as well as PKC [8, 9] . Hence, both complexes are important for effective regulation of the Akt/mTOR dual pathway, with the mTORC1 complex responsive towards growth factors, nutrients, energy, or oxidative stress indirectly while the mTORC2 complex plays an important role towards Akt activation to assist in complete activation of the PI3K/Akt/mTOR pathway.
ACTIVATION MECHANISM
Several receptor tyrosine kinases regulate the activation of the PI3K/Akt/mTOR pathway upon growth factor stimulation. Growth factors such as Insulin growth factor (IGF), epidermal growth factor (EGF), and Hepatocyte growth factor activate receptor tyrosine kinases (RTKs) via autophosphorylation on their tyrosine residues. Lipid kinases, such as PI3K, then associate with these phosphorylated tyrosine residues to activate the catalytic subunit of PI3Ks. For PI3Ks of class1A, the p110α catalytic subunit is activated upon p85α associating with the RTKs Activated PI3Ks further phosphorylate substrates like phosphatidylinositol 4,5biphosphate to phosphatidylinositol 3,4,5triphosphate (PIP3) within a few seconds. Secondary messengers such as PIP3 further recruit Akt to the membrane by interacting with the PHdomain of Akt. Upon membrane tran slocation, AKT gets activated by phosphorylation of its Ser473 and Thr308 residues by the PDK1 and mTORC2 complex respectively. Fully activated Akt then regulates several cellular processes by interacting with different substrates downstream of Akt. In the meanwhile, PTEN, a PIP3 phosphatase, acts a regulator of this pathway by maintaining homeostasis for this pathway activation. Activated Akt stimulates the mTORC1 complex by phosphorylating tuberous sclerosis complex2 (TSC2) and PRAS40, which are both negative regulators of mTOR. The mTORC1 complex controls protein translation and cell growth by phosphorylating ribosomal S6 kinase and the inhibitory partner of the translation initiation factor 4E (4EBP1), which are regulators of protein synthesis [10] . Thus, under normal physiological conditions, Akt regulates cellular dynamics such as cell growth, cytoskeletal reorganization, cell cycle progression, cell survival, cell proliferation, protein translation, and cellular metabolism by interacting with various substrates, which will now be discussed in more detail. [11] . Akt also plays an important role in regulating cell cycle progression in normal cells. It either directly phosphorylates or indirectly regulates the protein expression levels of several molecules of cell cycle progression at the G1/S and G2/M phase of the cell cycle. These substrates are mentioned in Table 1 .
CELLULAR ROLE OF THE AKT/mTOR PATHWAY

Cellular metabolism and protein synthesis
Cellular metabolism of carbohydrates into proteins, nucleotides, and lipids is a fundamental aspect of cell growth and proliferation, with nutrients acting as a fuel for cell growth. mTOR plays a crucial role in regulating this metabolism in response to nutrient availability. Of the two mTOR complexes, the mTORC1 complex plays a key role in regulating cellular metabolism [12] . It receives signals of activation from nutrients and growth factors. For example, during metabolism of carbohydrates, there is a spike in insulin levels, which activates the mTORC1 complex of the Akt/mTOR pathway via inhibition of the TSC1/2 complex by phosphorylation of TSC2 at multiple sites to inhibit TSC1 [13] . In this process, eventually Ras homolog enriched in brain (Rheb), a small GTPase belonging to the Ras family of guaninenucleotide G1 → S phase P-p21 at Thr145 residue [107] ↑ Transcription of c-MYC [108] Increase in CyclinD expression Decrease in cdk inhibitors: p21 cip1 , p21 kip1 , p15
INK4B
G2 → M phase P-Cdc25B at Ser353 [109] Cdc-25B inactivation Cyclin B activation P-Wee1Hu at Ser642 [110] Inactivation of Wee1Hu results in G2/M cell cycle progression P-Myt1 at Ser75 [111] Activation of Cyclin B-associated Cdk1 kinase activity S → G2 phase P-Cdk2 at Thr39 [112] Cytoplasmic shuttling of Cdk2 deregulation in GC [23] . This PIK3CA amplification was also associated with poor prognosis of GC patients.
PTEN (Phosphatase and tensin homolog), a tumor suppressor of the PI3K/Akt/mTOR pathway is frequently mutated or abnormally expressed in GC, with eventual functional inactivation of this gene product. Its inactivation is associated with increased progression towards gastric tumorigenesis. This inactivation is attributed to many possible mechanisms. While PTEN gene mutations are a rare phenomenon of PTEN inactivation, loss of heterozygosity of PTEN is more common in GC [24, 25] . Abnormal PTEN promoter hypermethylation at the CpG islands also inhibits PTEN expression in GC tissues [26] . Posttranscriptional repression of PTEN by microRNAs is another well studied mechanism of PTEN repression in GC. miR21 and miR221/222 have been identified as PTEN targets repressing PTEN expression by complexing with its 3'UTR region [2729] . PTEN also undergoes post translational modifications like phosphorylation for its regulation. A recent study indicated that increased phosphorylation of PTEN at the Ser380 residue and reduced expression of PTEN could contribute to PTEN inactivation in gastric tumor tissues [30] . Overall, PTEN inactivation has several functional consequences that fall in the category of hallmarks of cancer, such as angiogenesis and evading apoptosis. PTEN has been shown to elevate the apoptotic cascade via Fas/FasL or cytochromec mediated activation of capsase3 under normal physiological functions. Hence, with PTEN inactivation in GC cells, bypassing apoptosis via dysregulation of the apoptotic cascade will result in "evading apoptosis", a hallmark of cancer [31, 32] . PTEN is also known to be a negative modulator of endogenous VEGFmediated signaling. Thus, PTEN inactivation is associated with increased VEGF expression, and thereby potentiating angiogenesis in GC cells [33] . PTEN inactivation also results in constitutive activation of Akt, a PKB kinase regulating cell growth, cell death, and cell cycle. Using gastric tumor specimens, there has been a statistically significant correlation demonstrated between increased phosphorylation of Akt with poor prognosis of GC patients [3436] . Functionally, this constitutive expression of phosphorylated Akt further contributes towards hallmarks of cancer such as binding proteins that enhances apoptotic signalling at cellular levels [14] , is inhibited upon TSC1 complex inactivation. The mTORC1 complex is also stimulated in the presence of amino acids by promoting the conversion of Rasrelated GTPbinding protein (RAG) heterodimers (RAGA or RAGB, and RAGC or RAGD) into their active conformation, which further assists in mTORC1 complex cellular localization from the cytoplasm to the surface of the lysosome where it binds to inactivated RHEB [1517] . The activated mTORC1 complex also tightly regulates pathways such as the AMPactivated protein kinase (AMPK) pathway by preventing its activation in the presence of a high ATP/AMP ratio. However, in the absence of energy in cells, AMPK gets activated by phosphorylating TSC2 at Ser1387 and Raptor from the mTORC1 complex at Ser792, resulting in mTORC1 inactivation [18, 19] . After mTORC1 activation and subsequent complete activation of the Akt/mTOR pathway, immediate downstream substrates of mTORC1 complex such as S6K (ribosomal S6 kinase), 4EBP1, and ULK1 (UNC51 like kinase) are phosphorylated at different residues. Interestingly, activated S6K further phosphorylates Insulin receptor substrate1 (IRS1), upstream of mTORC1. Phosphorylation of IRS1 at serine residues by S6 kinases prevents IRS1 functions and thereby PI3K activation [20] . This negative feedback loop of the PI3K/Akt/mTOR pathway is an important aspect of maintaining homeostasis in cellular metabolism, protein synthesis, and cell growth.
ONCOGENIC POTENTIAL OF PI3K/AKT/ mTOR PATHWAY IN GC
Dysregulations caused by genetic alterations of the PI3K/Akt/mTOR pathway have been recently identified to play a crucial role in gastric oncogenesis. GC is the second most common cause of cancerrelated death worldwide. PIK3CA, the gene encoding the catalytic subunit p110 of PI3K, is frequently mutated in gastric carcinoma cell lines and tumor tissues. Some reports identify mismatch repair deficiency as one of the factors contributing towards the PIK3CA mutations [2123] . Another study suggested PIK3CA amplifications contributing towards the PI3K/Akt/mTOR pathway escaping cellular death pathways, cell cycle inhibition, and promoting survival and angiogenesis. One of the immediate downstream substrates of Akt is the FoxO family of transcription factors, which promotes growth inhibitory or/and proapoptotic signals by either regulating cell cycle inhibitory proteins such as p21 KIP1 or p27 WAF1/CIP1 or proapoptotic proteins of the Bcl2 family of proteins [37, 38] . Activated Akt phosphorylates FoxO and thereby inhibits transcriptional functions of this family of proteins, resulting in increased cell survival and proliferation [37] . Constitutive phosphorylation of FoxO is also correlated with increased expression of angiogenesisrelated molecules in gastric tumor tissues [37] . Akt also directly phosphorylates anti apoptotic proteins such as Bad at Ser136. Thus, GCs with increased Akt expression show elevated levels of P-Bad at Ser136 that are sufficient to promote cell survival [39] . Another important substrate of Akt that acts as an initiator of the mitochondrial apoptotic pathway is caspase9. Phosphorylation of capsase9 at Ser-196 results in its inactivation. There is a significant correlation between constitutive phosphorylation of Akt with caspase9 phosphorylation in gastric tumor tissues, although the mechanism still remains unclear [40] . This apoptosis resistance conferred by pAkt also occurs by regulating increased expression of survivin, an inhibitor of apoptosis protein with a significant correlation between pAkt and survivin expression levels in gastric tumor staging [39] . Prosurvival signals by Akt can also be intensified with its interaction with components of other signaling pathways such as the NFκB pathway. Akt can phosphorylate NFκB kinases such as IκB kinase (IKKα) at Thr23, resulting in a stimulatory phosphorylation and thereby NFκB activation. This further augments the expression of prosurvival signals in GC cells [41, 42] . Another immediate downstream target of Akt is the mTORC1 complex, which is activated by phosphorylation of TSC2 by Akt and subsequent TSC1/2 complex formation, which acts on RHEB (Ras homolog enriched in brain) to further phosphorylate mTOR at Ser2448 and thereby resulting in mTOR activation. Therefore, low expression or mutations in TSC1 are associated with a dysfunctional TSC1/2 complex and constitutively activated mTOCR1 complex [43] . Recent studies have identified high pmTOR expression to be associated with poor prognosis and with some clinicopathological characteristics in GC tumor spe cimens both independently and in combination with low TSC1 expression [44, 45] . A preliminary epidemiological study identified functional polymorphisms of mTORC1 contributing towards GC susceptibility in Eastern Chinese population [46] . With studies focussing on mTORC1 complex dysregulation and functional consequences, further studies are important to understand mTORC2 dysregulations, the cause of which still remains unclear. Immediate downstream effectors for the activated mTORC1 complex are p70S6K and 4EBP1. p70S6K phosphorylation and activation, which mainly occurs in the cytoplasm, results in translation of 40s ribosomal S6 protein, while phosphorylated 4EBP1 acts as a translational repressor. Recent studies have also shown p70S6K and mTOR regulating each other, with p70S6K also acting as a kinase for mTOR phosphorylation at Ser2448 [47] . Aberrant expression of pp70S6K is linked to GC carcinogenesis and its aggressiveness. Nuclear localization of this protein could have some inhibitory effects towards GC pathogenesis [48] .
PRECLINICAL STUDIES AND ONGOING
CLINICAL TRIALS WITH PI3K/AKT INHIBITORS
Involvement of several molecules of the PI3K/Akt/ mTOR pathways in GC carcinogenesis has eventually led to development of both single, as well as recently, dual inhibitors essential for molecular targeted therapy for GC.
PI3K inhibitors and GC
PI3K inhibitors are classified into three classes based on their selectivity for the ATPbinding cleft on PI3K and pharmacokinetic properties: panclass Ⅰ, isoform selective, and dual PI3K/mTOR inhibitors [49, 50] .
Pan-Class Ⅰ inhibitors
Panclass Ⅰ inhibitors have inhibitory effects against each isoform of p110 (PIK3CA). Several panclass Ⅰ inhibitors are under investigation for GC targeted therapy, since PIK3CA gene mutations comprise 25% of gastric tumors, resulting in PI3K dysregulation in GC [51] .
The first report of a molecular agent inhibiting PI3K was quecertin, which was, however, a nonspecific kinase inhibitor [52] . Eventually, more specific pan class Ⅰ inhibitors were identified, such as Wortmannin and a quecertin analogue, LY294002. Although both LY294002 and Wortmannin exhibited potent PI3Kinhibitory properties, there were considerable limitations for them to proceed towards clinical trials [5254] . LY294002 showed nonspecific targeting, a short halflife, and toxicity in vivo [55, 56] , while Wort mannin had limitations involving biological stability and short halflife [57] . To further improve on the pharmacological avail abilities, a structural analogue of Wortmannin, PX866 was developed.
PX-866:
PX866 is a semisynthetic panclass1, Wortmannin analogue with inhibitory concentrations in nanomolar ranges and better efficacy and a safer pharmacokinetic profile than Wortmannin. Pre clinical in vivo studies have shown its anticancer effect against several xenograft models of various cancers [57, 58] . It is currently in Phase Ⅱ clinical trials for patients with glioblastoma and head and neck cancer [59, 60] . PX866 recently also came under limelight for a multicenter trial for advanced solid tumors including gastric tumors. Data from the trial show that PX866 can be administered with endurable toxicity for patients with advanced solid tumors [61] . NVP-BKM120 (Buparlisib): NVPBKM120 is a potent panclass Ⅰ PI3K inhibitor with its activity in nanomolar ranges for all the isoforms of Class Ⅰ PI3K. Preclinical investigations have revealed its effectiveness in a diverse range of cancer cell lines, with increased sensitivity in tumors harboring PIK3CA mutations [62] . Similar results were also observed in a panel of GC cell lines [63] . Additionally, combination therapy using PI3K and STAT3 inhibitors showed better efficacy and a synergistic effect in GC cell lines harboring KRAS mutations. The STAT3 pathway is also known to be constitutively activated in GC [64] . Although preclinical studies on BKM120 in GC are still ongoing, it has reached Phase Ⅱ clinical trials for other cancers such as brain, breast, colorectal, endometrial, NSCLC, and renal cell carcinoma [49, 6567] . Thus, BKM120 has a potential to progress into clinical trials for GC treatment using targeted therapy.
ZSTK474: ZSTK474, a panclass 1 PI3K inhibitor inhibits all the four isoforms of PI3K and exhibits anti tumor activity in vivo against human tumor xenograft models [6870] . In vitro studies in GC cell lines suggest combination therapy of ZST474 and IGFR inhibitors for treating IGFRpositive cancers to overcome any intrinsic resistance to inhibition of PI3K/Akt/mTOR signaling, since overexpression of IGFR correlated with increased tyrosine phosphorylation on Insulin Receptor substrate, leading to increased PI3K activation. Hence, combination therapy with both ZST474 and IGFR inhibitors on GC cells with high IGFR expression exerted a superior therapeutic response [71] .
BAY80-6946:
BAY806946 is synthesized by Bayer healthcare and is a highly potent, selective, and reversible panclass Ⅰ inhibitor working in nanomolar concentrations against all the isoforms of p110. However, it shows preferential activity against p110α and β than p110 γ and δ in tumor cell lines and xenograft models [72] . BAY806946 demonstrated acceptable safety profiles in phase Ⅰ clinical trials for advanced solid tumors, and therefore, exhibiting a potential to be progressed to phase Ⅱ clinical trials for patients with advanced solid tumors.
Isoform specific PI3K inhibitors
PI3K isoform specific inhibitors were designed with an aim to provide comparable or superior efficacy than panclass Ⅰ inhibitors. Some of them under investigation for GC treatment will now be discussed.
BYL719:
BYL719 is an α-isoform specific PI3K inhibitor working at nanomolar concentrations with minimal activity against other PI3K isoforms [73] . With the PI3K/ Akt/mTOR pathway being frequently dysregulated in GC, BYL719 exhibited its inhibitory effects in synergy with another inhibitor LJM716, a ligand dependent as well as independent HER3 inhibitor, in GC xenograft models [74] . Interestingly, the combination study was done in HER2 positive GC cell lines, suggesting the sensitivity of this drug towards HER amplifications. BYL719 also recently completed Phase1b clinical trial for advanced stage GC in a combinational study with the HSP90 inhibitor AUY922 in patients whose tumors either harbour molecular alterations of PIK3CA or HER2 amplification [75] .
INK1117:
INK117 is another novel, selective p110α inhibitor. It is particularly more effective and sensitive to tumors bearing PIK3CA mutations. With good oral bioavailability in preclinical xenograft studies, it has entered a phaseⅠ study for advanced solid tumors including GC, to evaluate its safety, tolerability, pharmacokinetic and pharmacodynamic properties [76] .
Dual PI3K/mTOR inhibitors
PI3K/mTOR dual inhibitors inhibit PI3K and the downstream mTOR kinase activity by binding to the ATPbinding cleft of these enzymes. Relative to the single inhibitors, these drugs have the benefit of inhibiting mTORC1 and mTOCR2, as well as all the isoforms of PI3K. Evidence has suggested that the mTORC1/S6K axis has a "twoedge sword"like function in activation of the PI3K/mTOR pathway by promoting growth signals downstream of Akt, as well as mediating a potent negative feedback loop that restrains signaling via the insulin/IGFR and other RTKs. Dysregulation of this negative feedback loop has been reported to contribute towards resistance in cancers subjected to single inhibitors [77] . Hence, the need of dual PI3K/mTOR inhibitors arises with an aim to discover drugs with low toxicity and good pharmacokinetic profile.
NVP-BEZ235:
NVPBEZ235 is a novel dual ATP competitive PI3K and mTOR inhibitor for p110α/β/γ/δ and mTOR kinase, with inhibitory doses at nanomolar ranges. It first entered phase trials for breast cancer [78] . The effectiveness of BEZ235 has been investigated in both PIK3CA mutated and wild type cell lines in vitro and in xenograft models in vivo. The first group reporting an effect of BEZ235 on gastric xenografts showed reduced tumor growth for NCIN87 but not MKN45 or MKN28 xenografts. Interestingly, the reduction in tumor growth correlated with thymidine kinase expression and not PI3K/mTOR pathway inhibition [79] . Another group demonstrated in vitro increased sensitivity of AGS, PIK3CA mutated cells than for NCIN87 and MKN45, wild type PIK3CA GC cells [63] . Clinically, the response rate for BEZ235 was highest for patients with PIK3CA mutations than those without this mutation [80] . However, another recent study showed an increased antitumor response with BEZ235 alone or in combination with nabpaclitaxel in NCIN87, AGS, and SNU16 GC cells, independent of PIK3CA mutation status in vitro and in a SNU16 xenograft model in vivo [81] . Hence, with increasing preclinical studies focusing on using NVPBEZ235 for GC targeted therapy, and its gaining popularity in clinical trials for other cancers, NVPBEZ235 might be a good potential candidate drug to be considered for clinical trials for solid tumors such as GC.
VS-5884:
VS5884 is a dual PI3K and mTOR inhibitor, inhibiting all the isoforms of PI3K and both mTOR complexes (mTORC1 and mTORC2), with nanomolar inhibitory concentrations for a panel of cancer cell lines in vitro and increased sensitivity towards cell lines harboring PIK3CA mutations. It also exhibits a favourable pharmacokinetic profile in vivo. VS5884 shows a statistically significant inhibition of tumor growth in HERoverexpressing GC xenograft models (NCIN87). This drug also exhibits a synergistic response in these xenograft models with geftinib, an EGFR inhibitor (EGFRi), currently in phase Ⅱ trials for GC treatment. Since this drug has proven its efficacy for monotherapy and combination therapy in GC xenograft models [82] , these data provide a rationale for testing VS5884 in early phase clinical trials for GC patients.
PI-103:
PI103 is an ATPcompetitive PI3K and mTOR inhibitor with variable sensitivities towards different isoforms of p110 and mTOR at nanomolar concentrations. It was recently assessed for its synergistic effect to enhance the antitumor response for GC both in vitro and in vivo with 5FU treatment. This study suggested PI103 usage for enhancing 5FU chemotherapy for GC; with 5FU currently being used to treat GC patients but demonstrating limitations due to intervariability in response rate of these patients. This synergistic effect of PI103 with 5FU was also associated with PIK3CA mutations and reduction of downstream effectors of PI3K/Akt/mTOR pathway and thymidylate synthase, an enzyme that generates thymidylate precursors for DNA synthesis in vitro [83] .
Akt inhibitors and GC
The Akt signaling cascade controls a spectrum of tumorigenesis events such as cell growth, proliferation, survival, angiogenesis, invasion, and metastasis, as well as activation of the mTOR signaling cascade. Several mutations or amplifications in the Akt/mTOR signaling cascade contribute towards constitutive activation of Akt, which includes PTEN mutations and PIK3CA mutations, as well as overexpression/ amplification of Akt itself [8487] . With activated Akt playing a crucial role in tumorigenesis, several Akt inhibitors have been designed that have entered preclinical as well as clinical trials. Akt inhibitors that are currently being investigated for GC treatment include:
AZD5363: AZD5363 binds to and inhibits all the isoforms of Akt (Akt1, Akt2, and Akt3) with potency in the nanomolar range. Reports have suggested increased sensitivity towards AZD5363 in cancer cells harboring PIK3CA mutations, PTEN mutations, or HER2 amplifications both in vitro and in vivo [88] . This sensitivity of AZD5363 towards the activating mutations was also tested in GC xenograft models, one with a PIK3CA mutation and another with PTEN loss. AZD5363 exhibited a relatively more significant antitumor response towards PIK3CA mutant GC xenografts than those with PTEN loss alone. Interestingly, for GC xenografts with inactivated PTEN treated with a combination of AZ5363 and taxotrene, a synergistic and potent antitumor response was observed rather than monotherapy with AZD5363 [89] . Hence, selection of patients based on their mutational status would be beneficial for targeted therapy, which can eventually lead to more effective and tailored therapy either with single agents or in combination.
MK-2206:
MK2206 is a highly selective, allosteric Akt inhibitor, with higher potency for Akt1 and Akt2 isoforms than Akt3. Its efficacy was investigated both in vitro and in vivo as a single agent as well as in combination with several chemotherapeutic drugs or molecular targeted drugs (EGFRi) to overcome any potential resistance. This drug enhances the anti tumor response in combination therapy, making it a suitable and promising agent for the second line of therapy in cancer patients receiving chemotherapy or targeted therapy [90] . This drug is currently used in phase Ⅱ trials as a secondline therapy for gastric and gastroesophageal cancer [91] .
Perifosine: An oral anticancer agent and an Akt inhibitor, Perifosine has entered clinical trials for major human cancers. eIF4E is a downstream effector of the Akt/mTOR pathway, and increased levels of phosphorylated eIF4E and totaleIF4E correlate with increased GC in tumor tissues. A recent study showed that Perifosine treatment of GC cells with increased eIF4E expression (peIF4E) downregulated eIF4E expression, and thereby exerting an inhibitory effect on the Akt/mTOR pathway. Also, the combination of eIF4E inhibitor with Perifosine in these GC cells further sensitized the cells towards more effective treatment [92] . Another study of combination therapy in GC revealed the effectiveness of Perifosine in combination with a miR27a inhibitor, an oncogene that contributes to drug resistance in GC cells [93] . With more studies identifying the molecular mechanisms of Perifosine inhibition in GC, a recent study shows Perifosine inhibiting tumor growth in GC cells via inhibition of the Akt/GSK3β/CMYC signaling pathway, with significant downregulation of AEG1 (Astrocyte elevated gene), a gene reported to play an important role in cellular processes such as proliferation, apoptosis, and invasion [94] . Hence, Perifosine is a good potential therapeutic Akt inhibitor when used in combination therapies to overcome drug resistance, with scope for further progression into clinical trials.
TCN-PM:
Triciribine Phosphate Monohydrate (TCNPM) is a potent Akt inhibitor inhibiting all the three isoforms of Akt. In Phase Ⅰ studies of patients with solid tumors, where TCNPM was administered to patients with increased pAkt levels (as assessed by immuno histochemical staining), a moderate reduction in pAkt was observed after single TCNPM therapy, which may have been possibly due to a small sample size. Further studies to confirm its availability as a single agent as well as its efficacy in combination treatments would help to promote its importance for phase Ⅱ clinical trials for GC [95] .
mTOR inhibitors
mTOR is often dysregulated in GC, with several preclinical studies suggesting mTOR as a potential therapeutic target. mTOR forms two types of com plexes to perform its cellular function based on its interacting partner and substrate specificity, these being the mTORC1 and mTOR2 complex. The mTORC1 complex is rapamycin sensitive [96] ; rapamycin being the first mTOR inhibitor developed, while the mTORC2 complex is rapamycin insensitive. mTOR inhibitors are classified into two types based on their specificity for mTOR complexes: Rapalogs and mTORC1/2 inhibitors.
Rapalogs: Rapamycin and its analogs (referred as rapalogs), first form a complex with the intracellular receptor FK506 binding protein 12 (FKBP12) and then bind to a domain separate from the catalytic site of mTOR, preventing mTOR function. Rapalogs are effective against the mTOCR1 complex [97] . Some of the rapalogs under preclinical and clinical studies for GC treatment are as follows:
Temsirolimus: Temsirolimus binds to FKBP12, and the resultant proteindrug complex prevents mTORC1 activity. A Phase Ⅰ clinical study determined a favorable toxicity profile, maximum tolerated dose, pharmacokinetics, and anti-tumor efficacy in patients with advanced cancer including GC, making it a favorable drug to proceed towards phase Ⅱ trials [98] . Everolimus Everolimus is another oral mTORC1 complex inhibitor that has demonstrated good safety and clinical tolerability profile in Phase Ⅰ trials for several cancers including GC. Phase Ⅱ trials for patients with advanced GC treated with Everolimus exhibited a good median progression free survival (PFS). Phase Ⅲ trials for previously treated GC did not show a significant overall survival benefit vs best supportive care patients. However, the PFS for six months and the safety profile was significant, which highlights the need for predictive biomarkers for Everolimus treatment response in order to obtain better efficacy for this drug [99] .
Ridaforolimus: Ridaforolimus, a rapamycin analog, is under clinical investigation with its well defined antitumor response in preclinical studies. It showed a synergistic antitumor response in patients with solid tumors including GC, in a Phase Ib trial, where ridaforolimus was given in combination with capecitabine, a prodrug that converts into FU [100] .
mTORC1/2 inhibitors
Although mTORC1 inhibition by rapamycin analogs results in substantial tumor growth inhibition, drug resistance has been reported due to a negative feedback loop in the PI3K/Akt/mTOR pathway either via RTKs upregulation with increased Akt activation or crosstalk of PI3K with Ras signaling, leading to MAPK pathway activation. Hence, mTORC1/2 complex inhibitors have gained interest owing to their ability to act as ATPcompetitive inhibitors of mTOR kinase activity.
PP242: PP242 significantly inhibits mTOR kinase activity, inhibiting both mTORC1 and mTORC2 complex activities. It shows superior antiproliferative and anti angiogenesis effects in GC cell lines in vitro relative to rapamycin, indicating its promising potential as a therapeutic drug in future for GC [101] . Other mTORC1/2 inhibitors that have been under investigation for solid tumor treatment include AZD2014, AZD8055, and OSI027; however, there are currently no reports on their usage for GC treatment.
POTENTIAL BIOMARKERS FOR TARGETED THERAPY
The PI3k/Akt/mTOR pathway is activated in approxi mately 30%60% of GC tumors. Hence, targeted therapy using either single or dual Akt/mTOR inhibitors is under investigation in several clinical trials as summarized in Table 2 , with Everolimus, an mTOR inhibitor, being the only drug to date that has progressed towards phase Ⅲ trials for advanced GC patients [99] . Unfortunately, overall survival (OS) for GC patients treated with Everolimus was not significant; hence, identification of specific biomarkers for patient selection for Everolimus treatment would aid in more personalized therapy, with a potential for better efficacy and antitumor response. Although Everolimus failed to significantly improve the overall survival of patients with refractory advanced gastric cancer (AGC), an interesting case study showed satisfactory Everolimus monotherapy in a patient with refractory AGC harboring PIK3CA mutations and pS6 aberrations [102] ; indicating the importance of predictive biomarkers for various subpopulations of AGC for effective treatment. With studies ongoing for biomarker discovery for better prognosis with Everolimus treatment for AGC patients, some biomarkers that have been explored to predict Everolimus sensitivity in other cancers are PIK3CA/ PTEN genomic aberrations [103, 104] . With the lack of predictive biomarkers, the need arises to discover new molecules as surrogate markers to further segregate the AGC patient population for more efficient PI3K/Akt/mTOR pathway inhibition. Recent reports have also shown constitutive activation of the Akt/mTOR pathway being regulated by receptor interacting protein1 (RIP1), a key enzyme in the activation of survival pathways such as Akt/mTOR as well as NFκB [105] . RIP1 downregulates PTEN expression as well as suppresses the mTOR/PI3K feedback inhibitory loop, leading to potent activation of this pathway. At the same time, RIP1 also mediates activation of NFκB pathway, where TAK1 (TGFβ), a key regulator of the signaling cascade, is recruited to the TNFα receptor complex, which is a pivotal step for IKK (IκB kinase) activation. The NFκB pathway is aberrantly activated in several cancers including breast and GC, and recently, an oncogene DP103 (a DEAD box RNA helicase), was identified by our group to be upregulated in breast, prostate, gastric and colon cancers, and was shown to define the metastatic potential via activation of the NFκB pathway in two independent breast cancer cohorts [106] . DP103 regulates the NFκB pathway via direct interaction with TAK1 and thus, the DP103TAK1 protein complex regulates activation of NFκB in breast cancer [106] . With TAK1 activation also being RIP1 dependent, cross talk between the Akt/mTOR and NFκB pathways suggests exploring the role of DP103 as a future biomarker for GC upon aberrant PI3K/Akt/mTOR pathway activation. 
